<DOC>
	<DOC>NCT02935855</DOC>
	<brief_summary>Diabetic and nondiabetic patients will be evaluated if they had a first diagnosis of non-valvular atrial fibrillation and in therapy with non-vitamin K oral anticoagulants and with vitamin K oral anticoagulants.</brief_summary>
	<brief_title>ORal anticoaGulants in diAbetic and Nondiabetic Patients With nOn-valvular Atrial fibrillatioN (ORGANON)</brief_title>
	<detailed_description>Parameters evaluated: - anthropometric indices - glycated haemoglobin, basal and postprandial glycemia - lipid profile - small and dense LDL; oxidized LDL - I troponin - red and white cells count; platelets count - creatinin, transaminases, iron - fibrinogen, D-dimer, anti-thrombin III - Hs-CRP, metalloproteinases 2 and 9 - incidence of bleeding</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Edoxaban</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>nonvalvular atrial fibrillation nondiabetic patients type 1 and 2 diabetic patients patients with cancer patients with chronic inflammation diseases</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Diabetic patients</keyword>
	<keyword>nondiabetic patients</keyword>
</DOC>